STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	4/61-64	Abstract/methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4/61-64, 4/65-75 to 5/76-80	Abstrac t/methods and results
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	5/90-92, 5/96-97 to 6/98-102, 6/116-118	Introduction/Paragraph 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	6/119 to 7/120-123	Introduction/Paragraph 4
Methods				
Study design	4	Present key elements of study design early in the paper T1 mapping and feature tracking of Left ventricular remodeling in obstructive sleep apnea	7/126-128, 7/137-141	Methods/ Study design and population/ Paragraph 1, 2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7/127-129	Methods/ Study design and population/ Paragraph 1
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	7/127-138, 8/155-159	Methods/ Study design and population/ Paragraph 1, Methods/ Polysomnography parameters/ Paragraph 1

		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	7/136-138	Methods/ Study design and population/ Paragraph 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8/152-159	Methods/ Polysomnography parameters/ Paragraph 1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9/183-184 to 10/185-204	Methods/ Cardiac magnetic resonance imaging/ CMR image analysis/ Paragraph 1-3
Bias	9	Describe any efforts to address potential sources of bias	N/A	N/A
Study size	10	Explain how the study size was arrived at	12/237-242	Results/ Paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11/214-218, 8/157-159	Methods/ Statistical analysis/ Paragraph 1, Methods/ Polysomnography parameters/ Paragraph 1
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11/219-226 to 12/227-231	Methods/ Statistical analysis/ Paragraph 1
		(b) Describe any methods used to examine subgroups and interactions	11/219-225	Methods/ Statistical analysis/ Paragraph 1
		(c) Explain how missing data were addressed	N/A	N/A
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	7/136-138	Methods/ Study design and population/ Paragraph 1

		(e) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12/237-242	Results/ Paragraph 1
		(b) Give reasons for non-participation at each stage	N/A	N/A
		(c) Consider use of a flow diagram	12/240-241	Results/ Paragraph 1(Figure 2)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12/245-248 to 13/249, 13/254-60	Results/ Population characteristics/ Paragraph 1, 2
		(b) Indicate number of participants with missing data for each variable of interest	N/A	N/A
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A	N/A
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	N/A	N/A
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	12/240-242	Results/ Paragraph 1
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13/266-270 to 14/271, 14/276-283, 14/290-292 to 15/293-298	Results/ CMR results/ Paragraph 1-3
		(b) Report category boundaries when continuous variables were categorized	13/258-260	Results/ Population characteristics/ Paragraph 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	15/301-313	Results/ Factors related to LV

				remodeling indexes/ Paragraph 1
Discussion				
Key results	18	Summarise key results with reference to study objectives	16/320-325	Discussion/ Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20/404-411, 21/440-444 to 22/445-462	Discussion/ Paragraph 6, 9, 10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18/377-379 to 19/380-397, 20/412-422 to 21/423-444 to 22/445-452	Discussion/ Paragraph 2-4, 7-9
Generalisability	21	Discuss the generalisability (external validity) of the study results	22/450-452	Discussion/ Paragraph 9
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23/477-480	Acknowledgements

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Article Information: https://dx.doi.org/10.21037/cdt-22-38
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.